Atlas Wealth LLC Purchases New Position in Stryker Corporation $SYK

Atlas Wealth LLC bought a new position in Stryker Corporation (NYSE:SYK) during the 1st quarter, Holdings Channel reports. The firm bought 36,760 shares of the medical technology company’s stock, valued at approximately $12,079,000. Stryker comprises approximately 1.5% of Atlas Wealth LLC’s portfolio, making the stock its 19th biggest holding.

A number of other institutional investors and hedge funds also recently bought and sold shares of SYK. Cornerstone Planning Group LLC boosted its position in shares of Stryker by 23.2% during the first quarter. Cornerstone Planning Group LLC now owns 186 shares of the medical technology company’s stock worth $61,000 after purchasing an additional 35 shares in the last quarter. Gryphon Financial Partners LLC raised its stake in Stryker by 7.1% during the 1st quarter. Gryphon Financial Partners LLC now owns 1,861 shares of the medical technology company’s stock worth $611,000 after buying an additional 124 shares during the period. Assetmark Inc. raised its stake in Stryker by 791.0% during the 1st quarter. Assetmark Inc. now owns 35,693 shares of the medical technology company’s stock worth $11,728,000 after buying an additional 31,687 shares during the period. Angeles Wealth Management LLC lifted its holdings in Stryker by 4.0% during the first quarter. Angeles Wealth Management LLC now owns 1,986 shares of the medical technology company’s stock worth $654,000 after acquiring an additional 77 shares in the last quarter. Finally, Bessemer Group Inc. increased its holdings in shares of Stryker by 13.0% in the first quarter. Bessemer Group Inc. now owns 12,985 shares of the medical technology company’s stock worth $4,267,000 after acquiring an additional 1,495 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the sale, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 323,264 shares of company stock valued at $100,659,489. Company insiders own 4.60% of the company’s stock.

Key Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker launched Mako RPS, a new handheld robotic power system for total knee replacement, expanding its Mako robotics portfolio beyond robotic-arm assisted surgery and potentially broadening adoption of robotic-assisted orthopedic procedures. Stryker expands Mako robotics portfolio with full market release of Mako RPS
• Positive Sentiment: Media coverage highlighted the full U.S. commercial launch of Mako RPS, reinforcing investor optimism that Stryker is strengthening its competitive position in orthopedic robotics. Stryker fully launches Mako robotic power system for knee surgery in US
• Positive Sentiment: Unusually heavy call-option buying suggested traders were positioning for more upside in SYK, which can sometimes add momentum to the shares.
• Positive Sentiment: RBC Capital reiterated its Buy rating on Stryker, providing another favorable signal from the analyst community. RBC Capital Sticks to Their Buy Rating for Stryker (SYK)
• Neutral Sentiment: MarketWatch noted that Stryker stock outperformed peers on a strong trading day, indicating relative strength but without a specific new company catalyst. Stryker Corp. stock outperforms competitors on strong trading day
• Neutral Sentiment: Analyst commentary on Stryker was mixed in broader healthcare-sector coverage, but no major negative surprise was indicated in the headlines provided. Analysts Offer Insights on Healthcare Companies: Shionogi & Co (OtherSGIOF) and Stryker (SYK)

Stryker Trading Down 3.4%

Shares of SYK stock opened at $319.78 on Friday. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $404.87. The stock’s fifty day moving average price is $312.69 and its two-hundred day moving average price is $336.82. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The company has a market cap of $122.59 billion, a PE ratio of 37.01, a P/E/G ratio of 2.12 and a beta of 0.77.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. During the same quarter in the prior year, the business posted $2.84 earnings per share. Stryker’s revenue for the quarter was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities analysts predict that Stryker Corporation will post 14.99 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is 40.74%.

Analyst Ratings Changes

Several analysts have issued reports on the company. Wall Street Zen downgraded Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Wells Fargo & Company decreased their price objective on Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a report on Friday, May 1st. BMO Capital Markets began coverage on shares of Stryker in a research note on Wednesday, July 8th. They set an “outperform” rating and a $369.00 price target for the company. The Goldman Sachs Group restated a “neutral” rating and set a $361.00 target price on shares of Stryker in a report on Friday, May 1st. Finally, Canaccord Genuity Group decreased their target price on shares of Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a research report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and a consensus price target of $392.52.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.